Molecular mechanisms and targeting of colorectal cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 8, 2005, Pages 7-

  Vanhoefer, Udo ^a  

^a Dept of Internal Medicine Medical Oncology and Hematology Gastroenterology Infectious Diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; GEFITINIB; IRINOTECAN; LAPATINIB; PELITINIB; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; HAZARD ASSESSMENT; HUMAN; MONOTHERAPY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

EID: 28944453824     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.07.018     Document Type: Conference Paper

References (18)

1. E. Kaio, S. Tanaka, Y. Kitadai Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma Oncology 64 2003 61 73
2. T. Sternfeld, H.D. Foss, M. Kruschewski The prognostic significance of tumor vascularization in patients with localized colorectal cancer Int J Colorectal 14 1999 272 276
3. H.J. Choi, M.S. Hyun, G.J. Jung Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence Oncology 55 1998 575 581
4. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
5. F.F. Kabbinavar, J. Schulz, M. McCleod Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 Proc Am Soc Clin Oncol 23 249 2004 (abstr 3516)
6. J.M. Wood, G. Bold, E. Buchdunger PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2000 2178 2189
7. B. Morgan, A.L. Thomas, J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases Results from two phase I studies J Clin Oncol 21 2003 3955 3964
8. Schering AG and Novartis Pharma AG CONFIRM-1 Trial. Available at: http://www.schering.de/scripts/en/50_media/2005/pi/Q1/050321_adhoc_ptkzk.php?n= dc&c1=press_releases (accessed Oct 2005)
9. N.S. Goldstein, M. Armin Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma Implications for a standardized scoring system Cancer 92 2001 1331 1346
10. L. Saltz, M. Rubin, H. Hochster Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Proc Am Soc Clin Oncol 20 2001 A7 (abstr)
11. D. Cunningham, Y. Humblet, S. Siena Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) Proc Am Soc Clin Oncol 22 2003 252 (abstr 1012)
12. H.J. Lenz, R.J. Mayer, P.J. Gold Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. 22 suppl 2004 247s (abstr 3510)
13. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
14. U. Vanhoefer Novel molecular approaches in the therapy of advanced colorectal carcinoma Onkologie 26 suppl 7 2003 70 74
15. J.R. Hecht, A. Patnaik, I. Malik ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC) An updated analysis. 22 suppl 2004 247s (abstr 3511)
16. Braun AH, Dirsh O, Hilger RA,, et al. Preclinical evaluation of the combination of epidermal growth factor inhibitor ZD1839 (Iressa) and irinotecan (SN-38) in human colon cancer cells. Anticancer Drugs (in press)
17. C.D. Cho, G.A. Fisher, J. Halsey A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer Proc Am Soc Clin Oncol 22 2003 265 (abstr 1062)
18. Y. Wang, T. Jatkoe, Y. Zhang Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer J Clin Oncol 22 2004 1564 1571